Investors Watch Closely As Amanta Healthcare IPO Draws Near With Strong GMP Buzz

The much-anticipated IPO of Amanta Healthcare is set to open for subscription from September 1 to 3, 2025. As excitement builds in the market, investors and analysts are closely watching the Grey Market Premium (GMP) as an early indicator of listing gains and investor sentiment. With a price band fixed between ₹120 and ₹126 per share, the IPO has attracted considerable attention from retail and institutional investors alike.

Key Highlights From Amanta Healthcare IPO

IPO Subscription Dates: The bidding window for Amanta Healthcare will be open for three days from September 1 to 3, 2025.

Issue Price Band: Shares are priced between ₹120 and ₹126 each with a face value of ₹10.

Issue Size: The company plans to raise approximately ₹126 crore through a fresh issue of 1 crore shares.

Lot Size: The minimum lot for retail investors is 119 shares, amounting to around ₹14,994 based on the upper price band.

Listing: Post-IPO, shares will be listed on both BSE and NSE, with a tentative listing date of September 8, 2025.

Registrar: MUFG Intime India Private Limited is appointed as the registrar for handling IPO allotment and related processes.

Understanding The GMP And What It Indicates

The Grey Market Premium is the premium at which the shares are trading unofficially before the official listing. As of August 29, 2025:

The GMP stands at around ₹25 per share.

This suggests a probable listing price of approximately ₹151 per share, which translates to estimated listing gains of nearly 20%.

A healthy GMP often signals strong investor interest and confidence in the company’s prospects.

Investors use GMP trends to gauge market sentiment but should remember that GMP is unofficial and can fluctuate.

About Amanta Healthcare

Amanta Healthcare Limited operates in the pharmaceutical sector with a focus on development, manufacturing, and marketing of sterile liquid products, primarily parenterals. Some key points about the company include:

Specialized Product Line: The company uses advanced technologies like Aseptic Blow-Fill-Seal (ABFS) for producing IV fluids, diluents, eye drops, and respiratory care solutions.

Financial Performance: Revenue slightly dipped by 2% from ₹281.61 crores in March 2024 to ₹276.09 crores in March 2025, while Profit After Tax (PAT) surged by 189% from ₹3.63 crores to ₹10.50 crores.

Market Position: Amanta aims to capitalize on the growing demand for sterile liquid therapeutics in India and overseas.

Subscription And Allotment Details

Allotment date is expected on September 4, 2025, with refunds initiated by September 8 and credit to demat accounts also by September 8.

Retail investors have a reservation of at least 35% of the net issue, Non-Institutional Investors (HNIs) have 15%, and Qualified Institutional Buyers (QIBs) have up to 50%.

Given the GMP and company fundamentals, investors are advised to carefully assess their risk appetite before applying.

What Investors Should Consider

While an attractive GMP indicates potential listing gains, investors must evaluate the company’s long-term growth prospects and fundamentals.

Healthcare and pharmaceutical sectors have seen stable demand, but regulatory and market risks should not be overlooked.

Understanding the business model, competition, and market positioning is crucial to making an informed decision.

Staying updated on the subscription pattern and expert reviews can help gauge the IPO’s overall market response.

Conclusion

The Amanta Healthcare IPO is shaping up to be an exciting opportunity for investors looking to tap into the pharmaceutical niche. With strong GMP signals and a clear subscription timeline, the IPO is drawing considerable interest. However, as always in the investment world, it’s important to balance optimism with due diligence. The tentative listing date in early September will reveal more about the market’s reception to this offering.

Source: Economic Times Now, Univest, IPOWatch, SMC Global Securities, Times of India